Research Article
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
Table 2
Distribution of KRAS, PIK3CA, and BRAF mutations according to the status of patients.
| | Mutations | Patients alive/DOID | Patients DOD |
| | KRAS G12C | 1 | 0 | | KRAS G12D | 2 | 4 | | KRAS G12D + PIK3CA R108H | 0 | 1 | | KRAS G12D + G13D + G117N | 0 | 1 | | KRAS G12F | 0 | 1 | | KRAS G12R + PIKRCA E545K | 0 | 1 | | KRAS G12V | 2 | 3 | | KRAS G13D | 5 | 2 | | KRAS G13D + PIK3CA R88Q | 1 | 0 | | KRAS G13D + PIK3CA E545K | 0 | 1 | | KRAS Q61H | 1 | 0 | | KRAS A146T | 0 | 1 | | KRAS A 146T + PIK3CA R108H | 0 | 1 | | BRAF V600E | 1 | 2 | | Absent (WT) | 24 | 7 |
|
|
DOID: died of independent disease; DOD: died of disease.
|
